Comparative Pharmacology
Head-to-head clinical analysis: BAQSIMI versus GVOKE PFS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BAQSIMI versus GVOKE PFS.
BAQSIMI vs GVOKE PFS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BAQSIMI (glucagon) nasal powder is a hormone that increases blood glucose concentration by stimulating hepatic glycogenolysis and gluconeogenesis. It also relaxes smooth muscle of the gastrointestinal tract.
Glucagon receptor agonist; increases blood glucose levels by stimulating glycogenolysis and gluconeogenesis in the liver.
3 mg intranasally as a single dose for severe hypoglycemia.
1 mg subcutaneously as a single injection for severe hypoglycemia. May repeat once after 15 minutes if no response. For intramuscular or intravenous use: 1 mg IM or IV.
None Documented
None Documented
Glucagon has a short plasma half-life of approximately 8–18 minutes after IV administration. For nasal glucagon (BAQSIMI), systemic half-life is similar; clinical effect is brief, and rapid clearance limits duration.
Terminal elimination half-life is approximately 3-6 minutes (intravenous); clinical effect wanes rapidly as glucagon is cleared, requiring continuous infusion for sustained effect.
Primarily renal: metabolites and unchanged drug are excreted in urine. No significant biliary/fecal excretion data reported; glucagon is degraded in plasma, liver, and kidneys.
Glucagon is primarily degraded in the liver, kidneys, and plasma by proteolytic enzymes. Renal excretion accounts for <10% as unchanged drug; metabolites are excreted in urine and bile.
Category C
Category C
Glucagon (Antihypoglycemic)
Glucagon (Antihypoglycemic)